Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Edgewise Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Edgewise Therapeutics, Inc.’s stock price such as:

• Edgewise Therapeutics, Inc.’s current stock price and volume
• Why Edgewise Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for EWTX from analysts
• EWTX’s stock price momentum as measured by its relative strength

About Edgewise Therapeutics, Inc. (EWTX)

Before we jump into Edgewise Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Want to learn more about Edgewise Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Edgewise Therapeutics, Inc..

Edgewise Therapeutics, Inc.’s Stock Price as of Market Close

As of July 02, 2026, 4:00 PM, CST, Edgewise Therapeutics, Inc.’s stock price was $39.560.

Edgewise Therapeutics, Inc. is up 1.05% from its previous closing price of $39.150.

During the last market session, Edgewise Therapeutics, Inc.’s stock traded between $38.360 and $39.810. Currently, there are approximately 107.12 million shares outstanding for Edgewise Therapeutics, Inc..

Edgewise Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Edgewise Therapeutics, Inc. Stock Price History

Edgewise Therapeutics, Inc.’s (EWTX) price is currently down 2.63% so far this month.

During the month of July, Edgewise Therapeutics, Inc.’s stock price has reached a high of $41.860 and a low of $38.360.

Over the last year, Edgewise Therapeutics, Inc. has hit prices as high as $43.930 and as low as $12.300. Year to date, Edgewise Therapeutics, Inc.’s stock is up 59.42%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Edgewise Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 02, 2026, there was 1 analyst who downgraded Edgewise Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Edgewise Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Edgewise Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Edgewise Therapeutics, Inc. (EWTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Edgewise Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 02, 2026, Edgewise Therapeutics, Inc. has a weighted four-quarter relative price strength of 23.28%, which translates to a Momentum Score of 92 and is considered to be Very Strong.

Want to learn more about how Edgewise Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Edgewise Therapeutics, Inc. Stock Price: Bottom Line

As of July 2, 2026, Edgewise Therapeutics, Inc.’s stock price is $39.560, which is up 1.05% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Edgewise Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.